Advertisement

Bipolar Disorder

Risk for Cardiovascular Disease?
  • C. GesiEmail author
  • B. Carpita
  • F. M. Barberi
  • A. Cordone
  • L. Dell’Osso
Living reference work entry
  • 11 Downloads

Abstract

In recent years, epidemiologic research has consistently documented a significant clustering of medical and psychiatric conditions. In most cases, this comorbidity has been shown to enhance morbidity, loss of quality of life, and mortality, presenting a considerable challenge to clinical management, interdisciplinary communication, and healthcare costs. On the other hand, recognizing unique patterns of association between medical and psychiatric illnesses has born the chance of shading a new light on the mechanisms underpinning both kinds of morbidity.

The relationship between cardiovascular diseases (CVDs) and mood disorders (MDs) is one that gained growing interest in the last decades. In many instances, MDs were considered consequential to CVDs, especially when depression was involved. However, research has also begun to test the hypothesis that a common underlying process might be linking together CVDs and MDs, which may likely be the case of bipolar disorder (BPD). However, a third possibility may also hold true: BPD may increase the risk of developing CVDs, either directly or promoting the development of classical cardiovascular risk factors. Whatever is the case, it seems unlikely that the association between CVDs and BPD merely represents the co-occurrence of two simultaneous but independent conditions. From this perspective, the present chapter aims to review and summarize recent knowledge on the relationship among BPD and CVDs, devoting special attention to factors that may contribute to both diseases, as manifestations of a complex, systemic pathological process.

Keywords

Bipolar disorder Mood disorders Cardiovascular disease Coronary heart disease Pathophysiology Behavioval risk factors Cardiovascular risk factors 

References

  1. 1.
    World Health Organization (WHO). Fact sheet. 2017.Google Scholar
  2. 2.
    Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, Huang B. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005;66(10):1205–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Kilbourne AM, Cornelius JR, Han X, Pincus HA, Shad M, Salloum I, Conigliaro J, Haas GL. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6(5):368–73.PubMedCrossRefGoogle Scholar
  4. 4.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: Author; 2013.CrossRefGoogle Scholar
  5. 5.
    Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543–52.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Post RM, Luckenbaugh DA, Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE, McElroy SL, Nolen WA, Kupka R, Grunze H, Walden J. Incidence of childhood-onset bipolar illness in the USA and Europe. Br J Psychiatry. 2008;192(2):150–1.PubMedCrossRefGoogle Scholar
  7. 7.
    Westman J, Hällgren J, Wahlbeck K, Erlinge D, Alfredsson L, Ösby U. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;4(3):e002373.CrossRefGoogle Scholar
  8. 8.
    Kupfer J. The increasing medical burden in bipolar disorder. JAMA. 2005;293(20):2528–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 2015;72:334–41.CrossRefGoogle Scholar
  10. 10.
    Correll CU. Elevated cardiovascular risk in patients with bipolar disorder: when does it start and where does it lead? J Clin Psychiatry. 2008;69(12):1948–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuveer G, Stoney CM, Wasiak H, McCrindle BW. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease. A scientific statement from the American Heart Association. Circulation. 2015;132:965–86.PubMedCrossRefGoogle Scholar
  12. 12.
    De Hert M, Detraux J, Vncampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci. 2018;20(1):31–40.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Kessing LV, Vradi E, Andersen PK. Life expectancy in bipolar disorder. Bipolar Disord. 2015;17:543–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Osby U, Brandt L, Correia N, Ekbom A, Sparn P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord. 1994;31:91–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldstein B. Bipolar disorder and the vascular system: mechanisms and new prevention opportunities. Can J Cardiol. 2017;33(12):1565–157.PubMedCrossRefGoogle Scholar
  17. 17.
    Callaghan RC, Khizar A. The incidence of cardiovascular morbidity among patients with bipolar disorder: a population-based longitudinal study in Ontario. J Affect Disord. 2010;122(1–2):118–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Fiedorowicz JG, Solomon DA, Endicott J, Leon AC, Li C, Rice JP, Coryell WH. Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med. 2009;71(6):598–606.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Hatch JK, Scola G, Olowoyeye O, Collins JE, Andreazza AC, Moody A, Levitt AJ, Strauss BH, Lanctot KL, Goldstein BI. Inflammatory markers and brain-derived neurotrophic factor as potential bridges linking bipolar disorder and cardiovascular risk among adolescents. J Clin Psychiatry. 2017;78(3):286–93.CrossRefGoogle Scholar
  20. 20.
    Kessing LV, Vradi E, McIntyre RS, Andersen PK. Causes of decreased life expectancy over the life span in bipolar disorder. J Affect Disord. 2015;180:142–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE. Obesity among those with mental disorders: a National Institute of mental health meeting report. Am J Prev Med. 2009;36:341–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Mannie ZN, Williams C, Diesch J, Steptoe A, Leeson P, Cowen PJ. Cardiovascular and metabolic risk profile in young people at familial risk of depression. Br J Psychiatry. 2013;203:18–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Rottenberg J, Yaroslavsky I, Carney RM, Freedland KE, George CJ, Baji I, Dochnal R, Gádoros J, Halas K, Kapornai K, Kiss E, Osváth V, Varga H, Vetr A, Kovacs M. The association between major depressive disorder in childhood and risk factors for cardiovascular disease in adolescence. Psychosom Med. 2014;76:122–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Muller AH, Manji HM. On redefining the role of the immune system in psychiatric disease. Biol Psychiatry. 2006;60(8):796–8.CrossRefGoogle Scholar
  25. 25.
    Sayuri Yamagata A, Brietzke E, Rosenblat JD, Kakar R, McIntyre RS. Medical comorbidity in bipolar disorder: the link with metabolic inflammatory systems. J Affect Disorder. 2017;211:99–106.CrossRefGoogle Scholar
  26. 26.
    Versace A, Andreazza AC, Young LT, Fournier JC, Almeida JRC, Stiffler RS, Lockovich JC, Asiam HA, Pollock MA, Park H, Nimgaonkar VL, Kupfer DJ, Philips ML. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry. 2014;19:200–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 1998;22(1):1–33.CrossRefGoogle Scholar
  28. 28.
    Aktas O, Ulrich O, Infante-Duarte C, Nitsch R, Zipp F. Neuronal damage in brain inflammation. Arch Neurol. 2007;64(2):785–9.CrossRefGoogle Scholar
  29. 29.
    Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3- dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:702–21.CrossRefGoogle Scholar
  30. 30.
    Noto C, Rizzo LB, Mansur RB, McIntyre RS, Maes M, Brietzke E. Targeting the inflammatory pathway as a therapeutic tool for major depression. Neuroimmunomodulation. 2014;21:131–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, Landén M, Engberg G. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci. 2011;36:114–8.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Rolstad S, Jakobsson J, Sellgren C, Isgren A, Ekman CJ, Bjerke M, Blennow K, Zetterberg H, Pålsson E, Landén M. CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. Eur Neuropsychopharmacol. 2015;25:1091–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Munkholm K, Vinberg M, Vedel KL. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16–27.PubMedCrossRefGoogle Scholar
  35. 35.
    Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’Anna M, Mascarenhas M, Vargas AE, Chies JA, Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ortiz-Dominguez A, Hernandez ME, Berlanga C, Gutiérrez-Mora D, Moreno J, Hinze G, Pavòn L. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596–602.PubMedCrossRefGoogle Scholar
  37. 37.
    Maes M, Bosman E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptic and mood stabilizers. J Psychiatr Res. 1995;29(2):141–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Kauer-Sant’Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447–58.PubMedCrossRefGoogle Scholar
  39. 39.
    Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:952–5.CrossRefGoogle Scholar
  40. 40.
    Drago A, Crisafulli C, Calabro M, Serretti A. Enrichment pathway analysis. The inflammatory genetic background in bipolar disorder. J Affect Disord. 2015;179:88–94.PubMedCrossRefGoogle Scholar
  41. 41.
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–96.PubMedCrossRefGoogle Scholar
  42. 42.
    Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M, Neveu PJ. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology. 2001;26:797–808.PubMedCrossRefGoogle Scholar
  43. 43.
    Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat. 2013;70:31–41.CrossRefGoogle Scholar
  44. 44.
    Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141(1):1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–17.PubMedCrossRefGoogle Scholar
  46. 46.
    Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. C-reactive protein alterations in bipolar disorder: a meta-analysis. J Clin Psychiatry. 2015;76:142–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Soczynska JK, Kennedy SH, Woldeyohannes HO, Liauw SS, Alsuwaidan M, Yim CY, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. NeuroMolecular Med. 2011;13(2):93–116.PubMedCrossRefGoogle Scholar
  48. 48.
    Bond DJ, Andreazza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky J, et al. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology. 2016;65:76–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(4):17–22.CrossRefGoogle Scholar
  50. 50.
    Drake C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR, Hulme S, Georgiou R, Hinz R, Gerhard A, Vail A, Prenant C, Julyan P, Maroy R, Brown G, Smigova A, Herholz K, Kassiou M, Crossman D, Francis S, Proctor S, Russel JC, Hookins SL, Tvrrell P, Rothweil N, Alllan S. Brain inflammation is induced by co-morbidities and risk factor for stroke. Brain Behav Immun. 2011;25:1113–22.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedCrossRefGoogle Scholar
  52. 52.
    Hannson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015;278(5):483–93.CrossRefGoogle Scholar
  53. 53.
    Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC Jr, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC Jr, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Griffiths DJ. Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):1017.Google Scholar
  55. 55.
    Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(2):253–9.CrossRefGoogle Scholar
  56. 56.
    Lorgis L, Amoureux S, de Maistre E, Sicard P, Bejot Y, Zeller M, Vergely C, Sequeira-Le-Grand A, Lagrost AC, Nerchoud J, Cottin Y, Rohcette L. Serum brain derived neurotrophic factor and platelet activation evaluated by soluble-P-selectin and soluble CD-40-ligand in patients with acute myocardial infarction. Fundam Clin Pharmacol. 2010;4:525–30.Google Scholar
  57. 57.
    Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, Magalhaes PVS, Amminger P, McGorry P, Malhi GS. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Behav Rev. 2011;35:804–17.CrossRefGoogle Scholar
  58. 58.
    Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, Young LT, Yatham LN. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34(4):263–71.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J Cell MolMed. 2006;10:389–406.CrossRefGoogle Scholar
  60. 60.
    Hatch J, Andreazza A, Olowoyeye O, Rezin GT, Moody A, Goldstein BI. Cardiovascular and psychiatric characteristics associated with oxidative stress markers among adolescents with bipolar disorder. J Psychosom Res. 2015;79(3):222–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Maes M, Ruckoanich M, Chang YS, Mahanonda N, Berk M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Progr Neuro-Psychopharmacol Biol Psychiatry. 2011;35(3):769–83.CrossRefGoogle Scholar
  62. 62.
    Assies J, Mocking RJT, Lok A, Ruhé HG, Pouwer F, Schene AH. Effects of oxidative stress on fatty acid- and one-carbon- metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand. 2014;130:163–80.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Fyhrquist F, Saijonmaa O, Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat Rev Cardiol. 2013;10:274–83.PubMedCrossRefGoogle Scholar
  64. 64.
    Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29–38.PubMedCrossRefGoogle Scholar
  65. 65.
    Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, Taylor VH, Dodd S, Frangou S, Hall GB, Fernandes BS, Kauer-Sant’Anna M, Yatham LN, Kapczinski F, Young LT. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47:321–32.PubMedCrossRefGoogle Scholar
  66. 66.
    Brown NC, Andreazza AC, Young LT. An updated metaanalysis of oxidative stress markers in bipolar disorder. J Psychiatr Res. 2014;218:61–8.CrossRefGoogle Scholar
  67. 67.
    Andreazza AC, Frey BN, Erdtmann B, Salvador M, Rombaldi F, Santin A, Gonçalves CA, Kapczinski F. DNA damage in bipolar disorder. Psychiatry Res. 2007;153:27–32.PubMedCrossRefGoogle Scholar
  68. 68.
    Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:697–702.CrossRefGoogle Scholar
  69. 69.
    Andreazza AC, Kauer-Sant’anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111:135–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2000;2:180–90.PubMedCrossRefGoogle Scholar
  71. 71.
    Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Clay HB, Sillivan S, Konradi C. Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci. 2011;29:311–24.PubMedCrossRefGoogle Scholar
  73. 73.
    Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, Kauer Sant’Anna M, Grassi-Oliveira R, Post RM. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32(4):675–92.PubMedCrossRefGoogle Scholar
  74. 74.
    Maas JW, Katz MM, Koslow SH, Swann A, Davis JM, Berman N, Bowden CL, Stokes PE, Landis H. Adrenomedullary function in depressed patients. J Psychiatr Res. 1994;28(4):357–67.PubMedCrossRefGoogle Scholar
  75. 75.
    Gold PW, Gabry KE, Yasuda MR, Chrousos GP. Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinol Metab Clin N Am. 2002;31(1):37–62.CrossRefGoogle Scholar
  76. 76.
    Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, O’Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. Circulation. 2001;104(17):2024–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, van Dyck R, Penninx BW. Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). Arch Gen Psychiatry. 2008;65:1358–67.PubMedCrossRefGoogle Scholar
  78. 78.
    Byrne ML, Sheeber L, Simmons JG, Davis B, Shortt JW, Katz LF, Allen NB. Autonomic cardiac control in depressed adolescents. Depress Anxiety. 2010;27:1050–6.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Voss A, Baier V, Schulz S, Bar KJ. Linear and nonlinear methods for analyses of cardiovascular variability in bipolar disorders. Bipolar Disord. 2006;8(1):441–52.PubMedCrossRefGoogle Scholar
  80. 80.
    Henry BL, Minassian A, Paulus MP, Geyer MA, Perry W. Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res. 2010;44(3):168–76.PubMedCrossRefGoogle Scholar
  81. 81.
    Quintana DS, Westlye LT, Kaufmann T, Rustan ØG, Brandt CL, Haatveit B, Steen NE, Andreassen OA. Reduced heart rate variability in schizophrenia and bipolar disorder compared to healthy controls. Acta Psychiatr Scand. 2016;133(1):44–52.PubMedCrossRefGoogle Scholar
  82. 82.
    Buccelletti E, Gilardi E, Scaini E, Galiuto L, Persiani R, Biondi A, Basile F, Silveri NG. Heart rate variability and myocardial infarction: systematic literature review and metaanalysis. Eur Rev Med Pharmacol Sci. 2009;13(4):299–307.PubMedGoogle Scholar
  83. 83.
    Björkander I, Forslund L, Ericson M, Rehnqvist N, Hjemdahl P, Kahan T. Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. Clin Physiol Funct Imaging. 2009;29:201–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Singh JP, Larson MG, Tsuji H, Evans JC, O’Donnell CJ, Levy D. Reduced heart rate variability and new-onset hypertension: insights into pathogenesis of hypertension: the Framingham Heart Study. Hypertension. 1998;32:293–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the Atherosclerosis Risk In Communities (ARIC) study. Diabetes. 2002;51:3524–31.PubMedCrossRefGoogle Scholar
  86. 86.
    Benichou T, Pereira B, Mermillod M, Tauveron I, Pfabigan D, Maqdasy S, Dutheil F. Heart rate variability in type 2 diabetes mellitus: A systematic review and metaanalysis. PLoS One. 2018;79:465–466.Google Scholar
  87. 87.
    Amare AT, Schubert KO, Klinger-Hoffmann M, Cohen-Woods S, Baune BT. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017;7(1):1007.CrossRefGoogle Scholar
  88. 88.
    McDonald ML, MacMullen C, Liu DJ, Leal SM, Davis RL. Genetic association of cyclic AMP signaling genes with bipolar disorder. Transl Psychiatry. 2012;2:e169.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937–48.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9.PubMedCrossRefGoogle Scholar
  92. 92.
    Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14:539–49.PubMedCrossRefGoogle Scholar
  93. 93.
    Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89:1025–78.PubMedCrossRefGoogle Scholar
  94. 94.
    Donaldson ZR, le Francois B, Santos TL, et al. The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription. Transl Psychiatry. 2016;6(3):e746.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Ohta Y, Kosaka Y, Kishimoto N, Wang J, Smith SB, Honig G, Kim H, Gasa RM, Neubauer N, Liou A, Tecott LH, Deneris ES, German MS. Convergence of the insulin and serotonin programs in the pancreatic β-cell. Diabetes. 2011;60(12):3208–16.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Pruitt K, Brown G, Tatusova T, Maglott D. The reference sequence (RefSeq) database. Rockville: National Center for Biotechnology Information; 2012.Google Scholar
  97. 97.
    Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev. 2008;29(7):777–822.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Bowden CL, Mosolov S, Hranov L, Chen E, Habil H, Kongsakon R, Manfredi R, Lin HN. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol. 2010;25(2):60–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Zuo S, Fries BE, Szafara K, Regal R. Valproic acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none? Pharm Ther. 2015;40:126–32.Google Scholar
  100. 100.
    Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs. CNS Drugs. 1998;9:135–51.CrossRefGoogle Scholar
  101. 101.
    Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013–24.PubMedCrossRefGoogle Scholar
  102. 102.
    Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002;24:1576–84.PubMedCrossRefGoogle Scholar
  103. 103.
    McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, Baker RA. A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord. 2011;13(6):PCC.11m01182.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Ezzaher A, Mouhamed DH, Mechri A, Neffati F, Douki W, Gaha L, et al. Thyroid function and lipid profile in bipolar I patients. Asian J Psychiatr. 2011;4:139–43.PubMedCrossRefGoogle Scholar
  105. 105.
    Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol. 2008;11:679–84.PubMedCrossRefGoogle Scholar
  106. 106.
    Schwarz E, Prabakaran S, Whiteld P, Major H, Leweke FM, Koethe D, et al. High throughput lipidomic proling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res. 2008;7:4266–77.PubMedCrossRefGoogle Scholar
  107. 107.
    Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011;12(5):e32–43.PubMedCrossRefGoogle Scholar
  108. 108.
    Rodriguezgil J, Guinovart J, Bosch F. Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. Arch Biochem Biophys. 1993;301:411–5.CrossRefGoogle Scholar
  109. 109.
    Li H, Fang M, Xu M, Li S, Du J, Li W, et al. Chronic olanzapine treatment induces disorders of plasma fatty acid pro le in Balb/c mice: a potential mechanism for olanzapine-induced insulin resistance. PLoS One. 2016;11:e0167930.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Tabata I, Schluter J, Gulve EA, Holloszy JO. Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes. 1994;43:903–7.PubMedCrossRefGoogle Scholar
  111. 111.
    Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54(1):1–13.PubMedCrossRefGoogle Scholar
  112. 112.
    Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–35.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015;4(2):e001568.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1–3):103–10.PubMedCrossRefGoogle Scholar
  115. 115.
    Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–33.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;4:CD006569.Google Scholar
  117. 117.
    Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006625.Google Scholar
  118. 118.
    Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, Kissling W, Leucht S. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624.Google Scholar
  119. 119.
    Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;1:CD006626.Google Scholar
  120. 120.
    Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–81.PubMedCrossRefGoogle Scholar
  121. 121.
    Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008;192(6):406–11.PubMedCrossRefGoogle Scholar
  122. 122.
    Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first- generation versus second-generation medications: a systematic review and meta- analysis. Ann Intern Med. 2012;157(7):498–511.PubMedCrossRefGoogle Scholar
  123. 123.
    De Hert M, Einfinger G, Scherpenberg E, Wampers M, Peuskens J. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract. 2010;64(8):1109–15.PubMedCrossRefGoogle Scholar
  124. 124.
    Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf. 2007;16(8):882–90.PubMedCrossRefGoogle Scholar
  125. 125.
    Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135(2):113–22.PubMedCrossRefGoogle Scholar
  126. 126.
    Gonsai NH, Amin VH, Mendpara CG, Speth R, Hale GM. Effects of dopamine receptor antagonist antipsychotic therapy on blood pressure. J Clin Pharm Ther. 2018;43(1):1–7.PubMedCrossRefGoogle Scholar
  127. 127.
    Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001;3(4):181–8.PubMedCrossRefGoogle Scholar
  128. 128.
    Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Diaz FJ, James D, Botts S, Maw L, Susce MT, de Leon J. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord. 2009;11(2):154–65.PubMedCrossRefGoogle Scholar
  130. 130.
    Arias F, Arnsten JH, Cunningham CO, Coulehan K, Batchelder A, Brisbane M, Segal K, Rivera-Mindt M. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults. Addict Behav. 2016;60:137–43.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Nesvåg R, Knudsen GP, Bakken IJ, Høye A, Ystrom E, Surén P, Reneflot A, Stoltenberg C, Reichborn-Kjennerud T. Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(8):1267–76.PubMedCrossRefGoogle Scholar
  132. 132.
    Hidalgo-Mazzei D, Walsh E, Rosenstein L, Zimmerman M. Comorbid bipolar disorder and borderline personality disorder and substance use disorder. J Nerv Ment Dis. 2015;203(1):54–7.PubMedCrossRefGoogle Scholar
  133. 133.
    Degenhardt L, Stockings E, Strang J, Marsden J, Hall WD. Illicit drug dependence. In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, editors. Mental, neurological, and substance use disorders: disease control priorities, vol. 4. 3rd ed. Washington (DC): The International Bank for Reconstruction and Development/The World Bank; 2016. Chapter 6.Google Scholar
  134. 134.
    Comtois KA, Russo JE, Roy-Byrne P, Ries RK. Clinicians’ assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients. Biol Psychiatry. 2004;56(10):757–63.PubMedCrossRefGoogle Scholar
  135. 135.
    Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry. 1995;34(4):454–63.PubMedCrossRefGoogle Scholar
  136. 136.
    Garcia-Portilla MP, Saiz PA, Benabarre A, Florez G, Bascaran MT, Díaz EM, Bousoño M, Bobes J. Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scand. 2010;121(6):437–45.PubMedCrossRefGoogle Scholar
  137. 137.
    Martínez-Gómez D, Eisenmann JC, Gómez-Martínez S, Veses A, Marcos A, Veiga OL. Sedentary behavior, adiposity and cardiovascular risk factors in adolescents: the AFINOS study. Rev Esp Cardiol. 2010;63:277–85.PubMedCrossRefGoogle Scholar
  138. 138.
    Vaccarino V, Votaw J, Faber T, Veledar E, Murrah NV, Jones LR, Zhao J, Su S, Goldberg J, Raggi JP, Quyyumi AA, Sheps DS, Bremner JD. Major depression and coronary ow reserve detected by positron emission tomography. Arch Intern Med. 2009;169:1668–76.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Chuang HT, Mansell C, Patten SB. Lifestyle characteristics of psychiatric outpatients. Can J Psychiatr. 2008;53:260–6.CrossRefGoogle Scholar
  140. 140.
    Penninx BW, Leveille S, Ferrucci L, van Eijk JT, Guralnik JM. Exploring the effect of depression on physical disability: longitudinal evidence from the established populations for epidemiologic studies of the elderly. Am J Public Health. 1999;89:1346–52.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Sylvia LG, Salcedo S, Bernstein EE, Baek JH, Nierenberg AA, Deckersbach T. Nutrition, exercise, and wellness treatment in bipolar disorder: proof of concept for a consolidated intervention. Int J Bipolar Disord. 2013;1(1):24.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Jacka FN, Pasco JA, Mykletun A, Williams LJ, Hodge AM, O’Reilly SL, Nicholson GC, Kotowicz MA, Berk M. Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry. 2010;167(3):305–11.PubMedCrossRefGoogle Scholar
  143. 143.
    Quirk SE, Williams LJ, O'Neil A, Pasco JA, Jacka FN, Housden S, Berk M, Brennan SL. The association between diet quality, dietary patterns and depression in adults: a systematic review. BMC Psychiatry. 2013;13:175.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Hall MH, Muldoon MF, Jennings JR, Buysse DJ, Flory JD, Manuck SB. Self-reported sleep duration is associated with the metabolic syndrome in midlife adults. Sleep. 2008;31(5):635–43.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Arora T, Jiang CQ, Thomas GN, Lam KB, Zhang WS, Cheng KK, Lam TH, Taheri S. Self-reported long total sleep duration is associated with metabolic syndrome: the Guangzhou Biobank Cohort Study. Diabetes Care. 2011;34(10):2317–9.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Gangwisch JE, Malaspina D, Babiss LA, Opler MG, Posner K, Shen S, Turner JB, Zammit GK, Ginsberg HN. Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent. Health Sleep. 2010;33(7):956–61.PubMedCrossRefGoogle Scholar
  147. 147.
    Kaneita Y, Uchiyama M, Yoshiike N, Ohida T. Associations of usual sleep duration with serum lipid and lipoprotein levels. Sleep. 2008;31(5):645–52.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Millar A, Espie CA, Scott J. The sleep of remitted bipolar outpatients: a controlled naturalistic study using actigraphy. J Affect Disord. 2004;80(2–3):145–53.PubMedCrossRefGoogle Scholar
  149. 149.
    Jones SH, Hare DJ, Evershed K. Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. Bipolar Disord. 2005;7(2):176–86.PubMedCrossRefGoogle Scholar
  150. 150.
    Harvey AG, Schmidt DA, Scarnà A, Semler CN, Goodwin GM. Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry. 2005;162(1):50–7.PubMedCrossRefGoogle Scholar
  151. 151.
    Soreca I, Wallace ML, Frank E, Hasler BP, Levenson JC, Kupfer DJ. Sleep duration is associated with dyslipidemia in patients with bipolar disorder in clinical remission. J Affect Disord. 2012;141(2–3):484–7.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardio-vascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med. 2012;172:686–94.PubMedCrossRefGoogle Scholar
  153. 153.
    Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68:1056–61.PubMedCrossRefGoogle Scholar
  154. 154.
    Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009;302:1651–7.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Noaghiul S, Hibbeln JR. Cross-national comparisons of sea- food consumption and rates of bipolar disorders. Am J Psychiatry. 2003;160:2222–7.PubMedCrossRefGoogle Scholar
  157. 157.
    McNamara RK, Jandacek R, Rider T, Tso P, Dwivedi Y, Pandey GN. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord. 2010;126:303–11.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Lin PY, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68:140–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • C. Gesi
    • 1
    • 2
    Email author
  • B. Carpita
    • 1
  • F. M. Barberi
    • 1
  • A. Cordone
    • 1
  • L. Dell’Osso
    • 1
  1. 1.Department of Clinical and Experimental MedicineUniversity of PisaPisaItaly
  2. 2.Department of PsychiatryASST Fatebenefratelli-SaccoMilanItaly

Section editors and affiliations

  • Matteo Rocchetti
    • 1
  1. 1.Department of Brain and Behavioral ScienceUniversity of PaviaPaviaItaly

Personalised recommendations